In 2023, the sales of nervous system medicines in Canada stood at 5.8 billion USD PPP. The forecast indicates a steady growth, with values increasing from 5.9 billion USD in 2024 to 6.42 billion USD PPP by 2028. The year-on-year growth rate evidences approximately 2.5% to 2.7%, while the compound annual growth rate (CAGR) over the five-year period averages around 2.6%. This consistent increase reflects a stable market demand and suggests ongoing advancements in healthcare and treatment options.

Future trends to watch for include:

Potential impacts of healthcare policy changes on drug pricing and accessibility.
Innovations in biotechnology and personalized medicine, which may disrupt traditional sales patterns.
Global supply chain dynamics affecting availability and cost.